天坛生物(600161.SH):终止静注COVID-19人免疫球蛋白(pH4)临床试验

智通财经
27 Dec 2024

智通财经APP讯,天坛生物(600161.SH)发布公告,公司下属国药集团武汉生物制药有限公司研制的“静注COVID-19人免疫球蛋白(pH4)”处于Ⅱ期临床试验研究阶段。近日,经综合评估,公司决定终止该药物的Ⅱ期临床试验研究及后续研发。

据称,静注COVID-19人免疫球蛋白(pH4)研发投入共计12,060.70万元,包括研究开发费和设备购置费。其中研究开发费累计共11,690.95万元,11,690.99万元已计入以前年度会计期间损益,-0.04万元计入2024年度损益。公司终止静注COVID-19人免疫球蛋白(pH4)的临床试验及后续研发事项,不会对公司未来的生产经营与业绩产生重大影响。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10